BAY 12-8039 (moxifloxacin) Phase III study of the treatment of skin and skin structure infections

Medicine and Dentistry

• Infection 100%
• Skin 60%
• Therapeutic Procedure 40%
• Moxifloxacin 40%
• Adverse Drug Reaction 40%
• Patient 20%
• Inpatient 20%
• Incidence 20%
• Antiinfective Agent 20%
• Assessment 20%
• Diarrhea 20%
• Quinolone 20%
• Functional Gastrointestinal Disorder 20%
• Symptom 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Infection 100%
• Adverse Drug Reaction 40%
• Moxifloxacin 40%
• Tablet 20%
• Incidence 20%
• Symptom 20%
• Antiinfective Agent 20%
• Organisms 20%
• Diarrhea 20%
• Nausea 20%
• Quinolone 20%
• Digestive System Function Disorder 20%
• Stomach Discomfort 20%